NASDAQ:MNKD MannKind (MNKD) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free MNKD Stock Alerts $4.62 +0.15 (+3.36%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$4.41▼$4.7450-Day Range$3.25▼$5.2752-Week Range$3.17▼$5.75Volume3.99 million shsAverage Volume4.17 million shsMarket Capitalization$1.25 billionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get MannKind alerts: Email Address MannKind MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside73.2% Upside$8.00 Price TargetShort InterestBearish13.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth166.67%From $0.06 to $0.16 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.06 out of 5 starsMedical Sector633rd out of 947 stocksPharmaceutical Preparations Industry290th out of 434 stocks 3.5 Analyst's Opinion Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, MannKind has a forecasted upside of 73.2% from its current price of $4.62.Amount of Analyst CoverageMannKind has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.22% of the outstanding shares of MannKind have been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in MannKind has recently increased by 3.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNKD. Previous Next 3.0 News and Social Media Coverage News SentimentMannKind has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for MannKind this week, compared to 2 articles on an average week.Search Interest32 people have searched for MNKD on MarketBeat in the last 30 days. This is an increase of 967% compared to the previous 30 days.MarketBeat Follows10 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of MannKind is held by insiders.Percentage Held by Institutions49.95% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for MannKind are expected to grow by 166.67% in the coming year, from $0.06 to $0.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is -92.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is -92.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About MannKind Stock (NASDAQ:MNKD)MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Read More MNKD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNKD Stock News HeadlinesMarch 19, 2024 | americanbankingnews.comCantor Fitzgerald Reaffirms "Overweight" Rating for MannKind (NASDAQ:MNKD)March 17, 2024 | finance.yahoo.comMNKD Mar 2024 5.000 putMarch 19, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 16, 2024 | finance.yahoo.comMNKD Mar 2024 4.000 callMarch 16, 2024 | finance.yahoo.comMNKD Mar 2024 4.500 putMarch 11, 2024 | msn.comWhat's Going On With MannKind Stock?March 11, 2024 | finance.yahoo.comINHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsMarch 11, 2024 | globenewswire.comINHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 10, 2024 | finance.yahoo.comMNKD Mar 2024 6.500 callMarch 9, 2024 | finance.yahoo.comMNKD Mar 2024 3.000 putMarch 8, 2024 | finance.yahoo.comMNKD Mar 2024 3.500 putMarch 5, 2024 | globenewswire.comMannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8March 4, 2024 | globenewswire.comMannKind Corporation Announces Participation at Upcoming ConferencesMarch 3, 2024 | ca.finance.yahoo.comMNKD Mar 2024 7.000 callMarch 3, 2024 | finance.yahoo.comAnalysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) ForecastsFebruary 29, 2024 | finance.yahoo.comMannKind Full Year 2023 Earnings: Beats ExpectationsFebruary 29, 2024 | uk.finance.yahoo.comMannKind Corporation (MNKD) stock price, news, quote & history – Yahoo FinanceFebruary 28, 2024 | markets.businessinsider.comMannKind Corporation: Strong Growth and Clinical Advancements Prompt Buy RatingFebruary 28, 2024 | finance.yahoo.comMannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comQ4 2023 MannKind Corp Earnings CallFebruary 27, 2024 | finance.yahoo.comMannKind Corp (MNKD) Reports Substantial Revenue Growth in 2023February 27, 2024 | globenewswire.comMannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development UpdateFebruary 22, 2024 | benzinga.comMannKind Stock (NASDAQ:MNKD) Insider TradesFebruary 20, 2024 | finance.yahoo.comMannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024February 20, 2024 | globenewswire.comMannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024February 16, 2024 | finance.yahoo.comMNKD Feb 2024 4.000 callSee More Headlines Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today3/19/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MNKD CUSIP56400P20 CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees411Year Founded1991Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.50 Potential Upside/Downside+73.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E Ratio77.00 P/E GrowthN/ANet Income$-11,940,000.00 Net Margins-6.00% Pretax Margin-5.22% Return on EquityN/A Return on Assets-3.62% Debt Debt-to-Equity RatioN/A Current Ratio3.59 Quick Ratio3.31 Sales & Book Value Annual Sales$198.96 million Price / Sales6.28 Cash FlowN/A Price / Cash FlowN/A Book Value($0.91) per share Price / Book-5.08Miscellaneous Outstanding Shares270,420,000Free Float259,601,000Market Cap$1.25 billion OptionableOptionable Beta1.27 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Michael E. Castagna Pharm.D. (Age 47)CEO & Director Comp: $1.26MMr. Steven B. Binder (Age 61)Chief Financial Officer Comp: $800.2kDr. David B. Thomson J.D. (Age 57)Ph.D., Executive VP, General Counsel & Secretary Comp: $798.53kDr. Stuart A. Tross Ph.D. (Age 57)Executive VP and Chief People & Workplace Officer Comp: $678.4kMr. Sanjay Singh M.B.A. (Age 58)Executive Vice President of Technical Operations Comp: $364.53kMs. Lauren M. Sabella (Age 63)Executive VP & COO Ms. Rosabel Realica Alinaya (Age 63)VP of Investor Relations & Treasury Comp: $402.26kMr. John F. Bedard (Age 74)Senior Vice President of Worldwide Regulatory Affairs Mr. James Patrick McCauley Jr. (Age 58)J.D., M.B.A., Chief Commercial Officer Comp: $614.06kDr. Matthew H. Nguyen PharmD (Age 54)Senior Vice President of Endocrine Business Unit More ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDIronwood PharmaceuticalsNASDAQ:IRWDGeronNASDAQ:GERNInnovivaNASDAQ:INVADynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 598,895 shares on 3/11/2024Ownership: 5.639%Wellington Management Group LLPBought 350,351 shares on 3/5/2024Ownership: 0.130%Goldman Sachs Group Inc.Bought 336,257 shares on 3/1/2024Ownership: 1.125%Virtu Financial LLCBought 44,737 shares on 2/26/2024Ownership: 0.036%Price T Rowe Associates Inc. MDBought 51,318 shares on 2/16/2024Ownership: 0.060%View All Insider TransactionsView All Institutional Transactions MNKD Stock Analysis - Frequently Asked Questions Should I buy or sell MannKind stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MNKD shares. View MNKD analyst ratings or view top-rated stocks. What is MannKind's stock price target for 2024? 3 Wall Street analysts have issued 1-year price targets for MannKind's shares. Their MNKD share price targets range from $6.50 to $10.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 73.2% from the stock's current price. View analysts price targets for MNKD or view top-rated stocks among Wall Street analysts. How have MNKD shares performed in 2024? MannKind's stock was trading at $3.64 at the beginning of the year. Since then, MNKD stock has increased by 26.9% and is now trading at $4.62. View the best growth stocks for 2024 here. When is MannKind's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MNKD earnings forecast. How were MannKind's earnings last quarter? MannKind Co. (NASDAQ:MNKD) posted its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.03. The biopharmaceutical company earned $51.20 million during the quarter, compared to the consensus estimate of $50.73 million. The business's revenue was up 56.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.06) earnings per share. What ETFs hold MannKind's stock? ETFs with the largest weight of MannKind (NASDAQ:MNKD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD). Who are MannKind's major shareholders? MannKind's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.66%), Vanguard Group Inc. (5.64%), Nitorum Capital L.P. (4.02%), Goldman Sachs Group Inc. (1.13%), Goldman Sachs Group Inc. (1.13%) and Northern Trust Corp (0.98%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross. View institutional ownership trends. How do I buy shares of MannKind? Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MNKD) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Companytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.